Literature DB >> 9873032

Differences in the regulation of fibroblast contraction of floating versus stressed collagen matrices.

F Grinnell1, C H Ho, Y C Lin, G Skuta.   

Abstract

To learn more about the regulation of contraction of collagen matrices by fibroblasts, we compared the ability of lysophosphatidic acid (LPA) and platelet-derived growth factor (PDGF) to stimulate contraction of floating and stressed collagen matrices. In floating collagen matrices, PDGF and LPA stimulated contraction with similar kinetics, but appeared to utilize complementary signaling pathways since contraction obtained by the combination of growth factors exceeded that observed with saturating concentrations of either alone. The PDGF-simulated pathway was selectively inhibited by the protein kinase inhibitor KT5926. In stressed collagen matrices, PDGF and LPA stimulated contraction with different kinetics, with LPA acting rapidly and PDGF acting only after an approximately 1-h lag period. Pertussis toxin, known to block signaling through the Gi class of heterotrimeric G-proteins, inhibited LPA-stimulated contraction of floating but not stressed matrices, suggesting that LPA-stimulated contraction depends on receptors coupled to different G-proteins in floating and stressed matrices. On the other hand, the Rho inhibitor C3 exotransferase blocked contraction of both floating and stressed collagen matrices. These results suggest the possibility that distinct signaling mechanisms regulate contraction of floating and stressed collagen matrices.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9873032     DOI: 10.1074/jbc.274.2.918

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  Interactions of fibroblasts with the extracellular matrix: implications for the understanding of fibrosis.

Authors:  B Eckes; D Kessler; M Aumailley; T Krieg
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Internet-based image analysis quantifies contractile behavior of individual fibroblasts inside model tissue.

Authors:  Steven Vanni; B Christoffer Lagerholm; Carol Otey; D Lansing Taylor; Frederick Lanni
Journal:  Biophys J       Date:  2003-04       Impact factor: 4.033

Review 3.  The myofibroblast, a key cell in normal and pathological tissue repair.

Authors:  Ian A Darby; Noraina Zakuan; Fabrice Billet; Alexis Desmoulière
Journal:  Cell Mol Life Sci       Date:  2015-12-17       Impact factor: 9.261

4.  Enhanced myofibroblastic differentiation and survival in Thy-1(-) lung fibroblasts.

Authors:  Yan Y Sanders; Pallavi Kumbla; James S Hagood
Journal:  Am J Respir Cell Mol Biol       Date:  2006-09-07       Impact factor: 6.914

Review 5.  Fibroblast mechanics in 3D collagen matrices.

Authors:  Sangmyung Rhee; Frederick Grinnell
Journal:  Adv Drug Deliv Rev       Date:  2007-08-14       Impact factor: 15.470

6.  RNA interference in human foreskin fibroblasts within the three-dimensional collagen matrix.

Authors:  Mark A Carlson; Amy K Prall; Jeremiah J Gums
Journal:  Mol Cell Biochem       Date:  2007-07-27       Impact factor: 3.396

7.  Aortic carboxypeptidase-like protein is expressed in fibrotic human lung and its absence protects against bleomycin-induced lung fibrosis.

Authors:  Scott L Schissel; Sarah E Dunsmore; Xiaoli Liu; Robert W Shine; Mark A Perrella; Matthew D Layne
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

8.  Expression of pro-inflammatory markers by human dermal fibroblasts in a three-dimensional culture model is mediated by an autocrine interleukin-1 loop.

Authors:  Daniela Kessler-Becker; Thomas Krieg; Beate Eckes
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

9.  Panx1 regulates cellular properties of keratinocytes and dermal fibroblasts in skin development and wound healing.

Authors:  Silvia Penuela; John J Kelly; Jared M Churko; Kevin J Barr; Amy C Berger; Dale W Laird
Journal:  J Invest Dermatol       Date:  2014-02-12       Impact factor: 8.551

10.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.